228 related articles for article (PubMed ID: 19350613)
1. Studies of benzamide- and thiol-based histone deacetylase inhibitors in models of oxidative-stress-induced neuronal death: identification of some HDAC3-selective inhibitors.
Chen Y; He R; Chen Y; D'Annibale MA; Langley B; Kozikowski AP
ChemMedChem; 2009 May; 4(5):842-52. PubMed ID: 19350613
[TBL] [Abstract][Full Text] [Related]
2. Functional differences in epigenetic modulators-superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies.
Kozikowski AP; Chen Y; Gaysin A; Chen B; D'Annibale MA; Suto CM; Langley BC
J Med Chem; 2007 Jun; 50(13):3054-61. PubMed ID: 17539623
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective HDAC inhibition from cysteine-derived zinc-binding groups.
Butler KV; He R; McLaughlin K; Vistoli G; Langley B; Kozikowski AP
ChemMedChem; 2009 Aug; 4(8):1292-301. PubMed ID: 19551801
[TBL] [Abstract][Full Text] [Related]
4. Chiral mercaptoacetamides display enantioselective inhibition of histone deacetylase 6 and exhibit neuroprotection in cortical neuron models of oxidative stress.
Kalin JH; Zhang H; Gaudrel-Grosay S; Vistoli G; Kozikowski AP
ChemMedChem; 2012 Mar; 7(3):425-39. PubMed ID: 22234885
[TBL] [Abstract][Full Text] [Related]
5. Thiol-based SAHA analogues as potent histone deacetylase inhibitors.
Suzuki T; Kouketsu A; Matsuura A; Kohara A; Ninomiya S; Kohda K; Miyata N
Bioorg Med Chem Lett; 2004 Jun; 14(12):3313-7. PubMed ID: 15149697
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ
J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227
[TBL] [Abstract][Full Text] [Related]
9. Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
Tessier P; Smil DV; Wahhab A; Leit S; Rahil J; Li Z; Déziel R; Besterman JM
Bioorg Med Chem Lett; 2009 Oct; 19(19):5684-8. PubMed ID: 19699639
[TBL] [Abstract][Full Text] [Related]
10. Structural biasing elements for in-cell histone deacetylase paralog selectivity.
Wong JC; Hong R; Schreiber SL
J Am Chem Soc; 2003 May; 125(19):5586-7. PubMed ID: 12733869
[TBL] [Abstract][Full Text] [Related]
11. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
Suzuki T; Matsuura A; Kouketsu A; Nakagawa H; Miyata N
Bioorg Med Chem Lett; 2005 Jan; 15(2):331-5. PubMed ID: 15603949
[TBL] [Abstract][Full Text] [Related]
12. Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors.
Anandan SK; Ward JS; Brokx RD; Bray MR; Patel DV; Xiao XX
Bioorg Med Chem Lett; 2005 Apr; 15(8):1969-72. PubMed ID: 15808449
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors.
Manku S; Allan M; Nguyen N; Ajamian A; Rodrigue J; Therrien E; Wang J; Guo T; Rahil J; Petschner AJ; Nicolescu A; Lefebvre S; Li Z; Fournel M; Besterman JM; Déziel R; Wahhab A
Bioorg Med Chem Lett; 2009 Apr; 19(7):1866-70. PubMed ID: 19272776
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
15. Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases.
Gu W; Nusinzon I; Smith RD; Horvath CM; Silverman RB
Bioorg Med Chem; 2006 May; 14(10):3320-9. PubMed ID: 16434199
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of thiazole-5-hydroxamic acids as novel histone deacetylase inhibitors.
Anandan SK; Ward JS; Brokx RD; Denny T; Bray MR; Patel DV; Xiao XY
Bioorg Med Chem Lett; 2007 Nov; 17(21):5995-9. PubMed ID: 17827005
[TBL] [Abstract][Full Text] [Related]
17. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.
Lu Q; Wang DS; Chen CS; Hu YD; Chen CS
J Med Chem; 2005 Aug; 48(17):5530-5. PubMed ID: 16107152
[TBL] [Abstract][Full Text] [Related]
18. Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxyurea, and oxazoline analogues of SAHA.
Hanessian S; Vinci V; Auzzas L; Marzi M; Giannini G
Bioorg Med Chem Lett; 2006 Sep; 16(18):4784-7. PubMed ID: 16870438
[TBL] [Abstract][Full Text] [Related]
19. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
Giannini G; Marzi M; Marzo MD; Battistuzzi G; Pezzi R; Brunetti T; Cabri W; Vesci L; Pisano C
Bioorg Med Chem Lett; 2009 May; 19(10):2840-3. PubMed ID: 19359173
[TBL] [Abstract][Full Text] [Related]
20. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs).
Schäfer S; Saunders L; Eliseeva E; Velena A; Jung M; Schwienhorst A; Strasser A; Dickmanns A; Ficner R; Schlimme S; Sippl W; Verdin E; Jung M
Bioorg Med Chem; 2008 Feb; 16(4):2011-33. PubMed ID: 18054239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]